Nicholson RI - Search Results

1

A good drug made better: the fulvestrant dose-response story.

Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM. Robertson JF, et al. Among authors: nicholson ri. Clin Breast Cancer. 2014 Dec;14(6):381-9. doi: 10.1016/j.clbc.2014.06.005. Epub 2014 Jun 24. Clin Breast Cancer. 2014. PMID: 25457991 Review.

2

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.

Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N. Kuter I, et al. Among authors: nicholson ri. Breast Cancer Res Treat. 2012 May;133(1):237-46. doi: 10.1007/s10549-011-1947-7. Breast Cancer Res Treat. 2012. PMID: 22286314 Clinical Trial.

3

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.

Agrawal A, Robertson JF, Cheung KL, Gutteridge E, Ellis IO, Nicholson RI, Gee JM. Agrawal A, et al. Among authors: nicholson ri. Int J Cancer. 2016 Jan 1;138(1):146-59. doi: 10.1002/ijc.29682. Epub 2015 Jul 30. Int J Cancer. 2016. PMID: 26178788 Free PMC article.

4

Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.

McClelland RA, Manning DL, Gee JM, Anderson E, Clarke R, Howell A, Dowsett M, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI. McClelland RA, et al. Among authors: nicholson ri. Breast Cancer Res Treat. 1996;41(1):31-41. doi: 10.1007/BF01807034. Breast Cancer Res Treat. 1996. PMID: 8932874

5

The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.

Gutteridge E, Agrawal A, Nicholson R, Cheung KL, Robertson J, Gee J. Gutteridge E, et al. Int J Cancer. 2010 Apr 15;126(8):1806-1816. doi: 10.1002/ijc.24884. Int J Cancer. 2010. PMID: 19739079 Free article. Clinical Trial.

6

Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.

Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S. Morgan L, et al. Cancer Biol Ther. 2009 Aug;8(16):1550-8. doi: 10.4161/cbt.8.16.8954. Cancer Biol Ther. 2009. PMID: 19830888

7

Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen.

Bundred NJ, Anderson E, Nicholson RI, Dowsett M, Dixon M, Robertson JF. Bundred NJ, et al. Among authors: nicholson ri. Anticancer Res. 2002 Jul-Aug;22(4):2317-9. Anticancer Res. 2002. PMID: 12174920 Clinical Trial.

8

Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization.

Gee JM, Nicholson RI. Gee JM, et al. Among authors: nicholson ri. Breast Cancer Res. 2003;5(3):126-9. doi: 10.1186/bcr584. Epub 2003 Feb 20. Breast Cancer Res. 2003. PMID: 12793892 Free PMC article. Review.

9

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Hutcheson IR, et al. Among authors: nicholson ri. Breast Cancer Res Treat. 2003 Sep;81(1):81-93. doi: 10.1023/A:1025484908380. Breast Cancer Res Treat. 2003. PMID: 14531500

10

The biology of antihormone failure in breast cancer.

Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I. Nicholson RI, et al. Breast Cancer Res Treat. 2003;80 Suppl 1:S29-34; discussion S35. doi: 10.1023/a:1025467500433. Breast Cancer Res Treat. 2003. PMID: 14535532 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page